+Compare
IMVT
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
4.85B

IMVT Immunovant Forecast, Technical & Fundamental Analysis

a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases.

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for IMVT with price predictions
07:00 PM EST Dec 03, 2023

IMVT's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for IMVT turned positive on November 28, 2023. Looking at past instances where IMVT's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 24, 2023. You may want to consider a long position or call options on IMVT as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

IMVT moved above its 50-day moving average on November 24, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMVT advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMVT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IMVT broke above its upper Bollinger Band on November 28, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IMVT entered a downward trend on November 20, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.704) is normal, around the industry mean (20.645). P/E Ratio (0.000) is within average values for comparable stocks, (137.286). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.397).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 6%. For the same Industry, the average monthly price growth was 26%, and the average quarterly price growth was 26%. MMIRF experienced the highest price growth at 247%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -31%. For the same stocks of the Industry, the average monthly volume growth was -48% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: 26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

IMVT is expected to report earnings to fall 7.13% to -41 cents per share on February 02

Immunovant IMVT Stock Earnings Reports
Q4'23
Est.
$-0.42
Q3'23
Est.
$-0.45
Q2'23
Missed
by $0.13
Q1'23
Missed
by $0.04
Q4'22
Missed
by $0.10
The last earnings report on November 09 showed earnings per share of -44 cents, meeting the estimate of -44 cents. With 1.80M shares outstanding, the current market capitalization sits at 4.85B.
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
320 West 37th Street
Phone
+1 917 580-3099
Employees
164
Web
https://www.immunovant.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QDEC23.37-0.02
-0.10%
FT Cboe Vest Nasdaq-100 Buffer ETF – Dec
UMAR31.10-0.07
-0.24%
Innovator S&P 500 Ultra Buffer ETF™ Mar
ISHP27.34-0.10
-0.36%
First Trust S-Network Glb E-Com ETF
TLTD65.50-0.53
-0.81%
FlexShares Mstar DevMks exUS FctTilt ETF
IXN64.98-0.78
-1.19%
iShares Global Tech ETF

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been closely correlated with SLNO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if IMVT jumps, then SLNO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
+0.64%
SLNO - IMVT
70%
Closely correlated
-2.98%
ROIV - IMVT
50%
Loosely correlated
+0.91%
BRNS - IMVT
48%
Loosely correlated
-4.44%
ICPT - IMVT
43%
Loosely correlated
N/A
ACST - IMVT
40%
Loosely correlated
+7.87%
More

Groups containing IMVT

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
+0.64%
IMVT
(undefined stocks)
95%
Closely correlated
-1.17%